- 1 Clinical Characteristics and Risk Factors for Myocardial Injury and
- 2 Arrhythmia in COVID-19 patients
- Hong Gang Ren^{1,2}, Xingyi Guo², Lei Tu³, Qinyong Hu⁴, Kevin Blighe⁵, Luqman
- 4 Bin Safdar⁶, Justin Stebbing⁷, Shepard D Weiner⁸, Monte S Willis⁹, Frits R
- 5 Rosendaal¹⁰, Guogang Xu¹¹, Feng Cao¹¹, Dao Weng Wang¹²
- ¹Department of Internal Medicine, Tongji Hospital, Tongji Medical College,
- 7 Huazhong University of Science and Technology, Wuhan, China.
- ²Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology
- 9 Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
- ³Division of Gastroenterology, Union Hospital, Tongji Medical college,
- Huazhong University of Science and Technology, Wuhan, China.
- ⁴Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
- ⁵Clinical Bioinformatics Research Ltd., London, UK.
- ⁶The Ministry of Agriculture and Rural Affairs, Wuhan 430062, China.
- ⁷Department of Surgery and Cancer, Division of Cancer, Imperial College
- London, Hammersmith Hospital Campus, Du Cane Road, London, UK.
- ⁸Division of Cardiology, Department of Medicine, Columbia University Medical
- 18 Center, New York, NY, USA.
- ⁹Section of Cardiology, Department of Pathology and Laboratory Medicine,
- Indiana University School of Medicine, Indianapolis, Indiana, USA.
- ¹⁰Department of Clinical Epidemiology and Department of Thrombosis and
- Haemostasis, Leiden University Medical Center, Leiden, The Netherlands.
- ¹¹The Second Medical Center & National Clinical Research Center for Geriatric
- 24 Diseases, Chinese PLA General Hospital, Beijing, China.
- ¹²Cardiovascular Department, Tongji Medical College, Huazhong University of
- Science and Technology, Wuhan, China.

- 27 Corresponding Authors:
- 28 **Prof. Feng Cao**, E-mail address: fengcao8828@163.com
- 29 **Prof. Dao Weng Wang,** E-mail address: <u>daowen.wang@foxmail.com</u>
- Disclosure: the authors have nothing to disclose.



ABSTRACT

- Background: Patients with COVID-19 can develop myocardial injury and
- arrhythmia during the course of their illness. However, the underlying risk
- factors for the development of cardiovascular related manifestations are
- 35 unclear.

- Methods: Using a register-based multi-center cross-sectional design, we
- analyzed 80 patients with myocardial injury and 401 controls, as well as 71
- patients with arrhythmia and 409 controls, all admitted with COVID-19.
- Putative risk factors for myocardial injury and arrhythmia were evaluated with
- 40 logistic regression with adjustment for potential confounders.
- 41 **Results:** COVID-19 patients with myocardial injury had fatigue (66.2%) and
- dyspnea (63.7%), while those with arrhythmia had dyspnea (71.8%). Patients
- with myocardial injury and arrhythmia had a significant mortality of 92.5% and
- 44 94.4%, respectively. A history of chronic obstructive pulmonary disease (COPD)
- or heart diseases was associated with an increased risk of myocardial injury
- 46 (odds ratio [OR] = 1.94, 95% confidence interval [CI]: 1.01-3.71; OR = 7.43, 95%
- 47 CI: 3.99-13.83) and arrhythmia (OR = 1.94, 95% CI: 1.00-3.75; OR = 13.16, 95%
- 48 CI: 6.75-25.68). In addition, we found that gamma glutamyltranspeptidase
- 49 (GGT) >50U/L (OR = 2.14, 95% CI: 1.37-3.32; OR = 1.85, 95% CI: 1.19-2.85),
- serum creatinine >111µmol/L (OR = 8.96, 95% CI: 4.4-18.23; OR = 3.71, 95%
- 51 CI: 2.01-6.85), serum sodium <136 mmol/L (OR = 4.68, 95% CI: 2.46-8.91; OR
- = 2.06; 95% CI: 1.06-4.00) were all associated with increased risk of
- myocardial injury and arrhythmia, respectively.
- 54 Conclusion: Our reported clinical characteristics and identified risk factors are
- important for clinical study of COVID-19 patients developing myocardial injury
- 56 and arrhythmia.

INTRODUCTION

58

59

60

61

62

63

64

65

66

67

68

69

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

The outbreak of new coronavirus disease (COVID-19) was characterized as a pandemic by World Health Organization on March 11, 2020^{1, 2}. COVID-19 may cause pneumonia with severe respiratory symptoms that may progress to acute respiratory distress syndrome (ARDS) and even death. Common signs of COVID-19 are fever, cough, muscle soreness, weakness, breathing difficulty and dyspnea³. During an infection, COVID-19 patients may develop varying degrees of myocardial injury³⁻⁶. In a previous study by Huang et al.¹, 5 out of 41 study participants were diagnosed with acute myocardial injury. The main manifestations of acute myocardial injury have been hypersensitive cardiac aggregates, troponin I (hs-cTnI) and elevated blood pressure. Most patients with significant myocardial injury required treatment in the Intensive Care Unit 70 (ICU)³⁻⁶. Other studies have shown that plasma biomarkers of myocardial injury, including creatine kinase (CK-MB), and troponin I were higher in ICU patients than those not treated in the ICU, providing evidence that ICU patients are more likely to develop cardiac complications such as myocardial injury³. It has been suggested that systemic inflammatory responses and immune system disorders lead to increased rates of cardiovascular symptoms^{1,7-9}. SARS-CoV-2 causes a severe inflammatory response, which may play a role in the development of myocardial infarction and arrhythmias. In a retrospective study of 138 hospitalized COVID-19 patients by Wang et al, nearly 17% of patients developed arrhythmia and 7.2% experienced acute cardiac injury³. The clinical presentation of COVID-19 patients with myocardial injury or arrhythmias is different in many ways from patients without cardiac involvement. Fatigue, anorexia, dyspnea, vomit and diarrhea are were more commonly observed for COVID-19 patients with myocardial injury or arrhythmias than the latter patients. To date, there has not been any clinical research investigating the risk factors related to myocardial injury and

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

arrhythmia in patients with COVID-19. Furthermore, there are no studies which explore whether or not the development of myocardial injury and arrhythmia influences the prognosis of COVID-19 patients, although intuitively, one would expect patients with cardiac manifestations to have a worse prognosis. Here, we have recruited 481 COVID-19 patients used a registry-based multi-center. cross-sectional design from a retrospective study. We evaluated clinical characteristics of 80 patients with myocardial injury and 71 patients with arrhythmias. We further evaluated the associations of potential risk factors with myocardial injury and arrhythmia caused by COVID-19. DOI for details **METHODS** Study design and data collection This was a retrospective cross-sectional study of medical records from three medical centers in Hubei province. Oral informed consent was obtained from all subjects, and the institutional review boards of all participating institutions approved the study protocol. We recruited 481 admitted COVID-19 patients from Wuhan Union West Hospital (n=265), Wuhan Hannan General Hospital (n=153) and Enshi General Hospital (n=63) from January 8th, 2020 to April 20th. 2020. The end-of-study date was April 24th, 2020. We reviewed nursing charts, clinical records, laboratory findings, and imaging results for patients with a COVID-19 diagnosis in the three hospital systems based on the National Health Commission and CDC, China protocol (the 5th edition). These data have not yet been published. Study outcomes Acute myocardial injury was defined by serum levels of troponin T (TnT) at the 99th percentile or greater, as previously described¹. Malignant arrhythmia was defined as rapid ventricular tachycardia lasting more than 30 seconds, inducing hemodynamic instability and/or ventricular fibrillation, as per the

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS). Health services utilization patterns were analyzed as binary variables (yes or no) to ventilation, antibiotics, antifungals, antiviral agents and hemodialysis. The following demographic and clinical features were identified from patients' medical records: socio-demographic variables included sex (male and female), race (Han, others), age (continuous variable), and smoking. Disease severities included the number of symptoms, unilateral or bilateral infection, and imaging characteristics (ground-glass opacification/opacity, yes/no). Comorbidity variables included cardiovascular diseases such as hypertension, underlying heart disease and coronary artery disease, chronic kidney and/or liver disease, chronic obstructive airways disease (COPD), diabetes and others. Laboratory tests analyzed included complete blood count, comprehensive metabolic panel (CMP) and clotting factors. Statistical Analysis Kruskal-Wallis tests were applied for continuous variables among patients from the three different regions. Categorical variables were displayed as counts or percentages. Chi-square tests were applied for categorical variables among patients from different regions. The associations of risk factors with myocardial injury and arrhythmia were evaluated using logistic regression models with an adjustment of potential confounders including after adjusting for age, gender, smoking status, and disease history. Continuous variables were summarized as medians. All statistical analyses were implemented using SAS, version 9.4 (SAS Institute, Inc.). A P value < 0.05 for a two-tailed test was considered statistically significant. **RESULTS** Clinic characteristics of study participants with myocardial injury

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

Socio-demographic and clinical characteristics of the 481 study participants including 80 cases of myocardial injury and 401 controls, were shown in Table 1. The median age (SD) of the study participants was 56. Of the patients with myocardial injury, 66.2% had fatigue and 63.7% had dyspnea. Disease severity was more likely to be higher in patients with myocardial injury (2.5% were mild, 2.5% were moderate and 95% were severe, P<0.001). In contrast, 2/3 of the control subjects had mild disease. Of the patients with myocardial injury, 7.5% recovered and were discharged from hospital, while 92.5% died (P<0.001). We observed that age was associated with an increased risk of myocardial injury case (P<0.01; Table 1). We also observed that there was a male predominance for myocardial injury (70% vs 30%, P=0.003; Table 1). There was no such male predominance in the control group. No significant associations with myocardial injury were observed for smoking status and maximum temperature during fever. Multivariate analysis between laboratory parameters and myocardial injury Patients with an abnormal GGT were associated with an increased risk of developing myocardial injury (OR = 2.14, 95% CI: 1.37-3.32; Table 2). Elevated serum creatinine (adjusted OR = 8.96, 95% CI: 4.4-18.23) and reduced serum sodium (adjusted OR = 4.68, 95% CI: 2.46-8.91) were also associated with an increased risk of myocardial injury. However, white blood cell count, lymphocyte count, total bilirubin, alanine aminotransferase, aspartate aminotransferase (AST) and blood urea nitrogen (BUN) did not appear to be associated with the risk of myocardial injury. In addition to these laboratory parameters, we observed that the uses of antibiotics (adjusted OR = 3.07, 95% CI: 1.58-5.95) and antiviral therapy (OR = 2.18, 95% CI: 1.2-3.93) were associated with an increased risk of myocardial injury. However, AST,

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

albumin, BUN did not appear to be associated with the risk of malignant arrhythmia caused by COVID-19. Clinic characteristics of study participants with arrythmias Socio-demographic and clinical characteristics of 71 cases of arrhythmia and 409 controls, were analyzed (Table 1). Patients with arrhythmia (Median age=61) had significantly older than controls (Median age=56) - 66.2% of cases were male. No significant differences were found for smoking status and highest fever between cases and controls. Of the 71 arrythmia cases, 71.8% had dyspnea – 95.8% participants with arrhythmia were classified as having severe COVID-19 disease. The outcome of patients with arrhythmia was poor, with only 5.6% recovering and being discharges and 94.4% dead (P<0.001). Multivariate analysis of laboratory parameters with arrythmias Table 2 illustrates the association between different laboratory parameters and arrythmias. Patients with increased GGT had a 1.85-fold increase in risk of arrhythmias when compared with those with normal GGT (95% CI:1.19-2.85). In addition, the elevated serum sodium was associated with increased risk of arrhythmia (adjusted OR = 2.06, 95% CI:1.06-4.00). In addition to these laboratory parameters, we observed that the uses of oxygen therapy (adjusted OR = 3.11, 95%CI: 1.65-5.83) and antibiotic therapy (OR = 2.03, 95%CI:1.1-3.76) were associated with an increased risk of arrhythmia. However, AST, albumin, and BUN did not appear to be associated with the risk of arrhythmia caused by COVID-19 as well. DISCUSSION In a large study of Covid-19 patients with and without myocardial injury and arrhythmia we found that older age, male sex, history of COPD and heart diseases, electrolyte disturbance and renal dysfunction were associated .With

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

the exception of asymptomatic carriers, most COVID-19 patients may develop pneumonia with severe respiratory symptoms^{1, 10}. The more severe cases progress to multiple organ failure or even death. It is believed that a cytokine release syndrome or cytokine storm which is triggered by the host response to the virus is responsible for acute injury to multiple organ systems including the heart, liver, and kidneys. It is becoming apparent that cardiovascular disease resulting from COVID-19 is not as uncommon as previously thought, and that the involvement of the heart prone to more severe disease and increased mortality. Thus, the identification of risk factors for arrythmias and acute myocardial injury is important for prognostication, in addition to early intervention, early diagnosis and treatment, which may help reduce morbidity and mortality. A previous study showed that 53.3% of COVID-19 patients with heart damage were men. In that study, myocardial injury was negatively correlated with age and the incidence of myocardial injury was lowest over the age of eighty. In our study, indicators of cardiac injury were generally negative in the patients with mild and moderate disease. AST, LDH, CTN I and MYO showed a strong correlation with myocardial injury. This is consistent with the results of Zhong et al. 11. We also found that patients who were not treated with glucocorticoids (GCs) and immunoglobulin therapy appeared to be at higher risk for heart damage. The protective role of GCs may be related to their immunosuppressive effects on leukocytes and endothelial cells to reduce the generation and release of pro-inflammatory cytokines that targetcardiomyocytes¹². The glucocorticoid receptor (GR) is expressed abundantly in cardiomyocytes, and the variability of acute cardiac injury may be related to polymorphisms of the glucocorticoid receptor. In addition, the GR can be selectively activated and cyclooxygenase (COX)-2 and prostaglandin (PG) biosynthesis in cardiomyocytes can be induced, which may help mediate cardioprotection^{13, 14}. Biosynthesis of prostaglandin can inhibit COX-2, and,

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

therefore, relieve inflammation derived myocardial damage in COVID-19 patients. We found that white blood cell numbers, lymphocyte numbers, neutrophil numbers, albumin, total bilirubin, alanine aminotransferase, AST, serum sodium, BUN, serum creatinine, GGT and myoglobin were positively correlated with myocardial injury. Elevated neutrophil counts led to a 3.35-fold increase in acute cardiac injury. Neutrophils are often the first type of leukocyte that infiltrate the heart in times of hyperimmune status. Their activation produces large amounts of inflammatory mediators, which mediate injury to the heart through the action of reactive oxygen species and proteolytic enzymes, leading to reduced oxygenation of the heart tissue 15-17. Neutrophils can also induce migration of They are also involved in macrophage migration to the infarct site in order to clear debris. The inflammatory process induced by neutrophils involves a process known as netosis through the generation of neutrophil extracellular traps (NETs). We observed a negative correlation between albumin levels and risk of myocardial injury. This relationship has never been reported¹⁸. Serum albumin (SA) may exert a cardio-protective effect by functioning as a natural inhibitor of the angiotensin-converting enzyme (ACE). ACE activity has also been associated with coronary vascular resistance in recent animal studies. The cardio-protective effect of ACE inhibition in cardiac surgery has been previously demonstrated 19-23. Within the physiological range of SA concentrations (35-52 mg/ml), almost all ACE is bound to albumin (and thus inactive). Below the physiological range of SA concentrations there is a rapid increase in the fraction of unbound (and thus active) ACE. The drop in SA in patients with heart damage is an important observation with potential therapeutic implications, including the close monitoring of albumin in patients admitted for COVID-19 pneumonia. Myoglobin, a useful marker of cardiac damage, has also been positively associated with a risk of heart damage²⁴.

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

In our study, the arrythmia group had a higher number of elderly subjects (except for age >80), whereas in the control group, there was an equal distribution in the <40, 40-60- and 60-80-year age categories. AST, LDH, CTN I and MYO also showed a strong correlation with arrhythmia. Patients who were not treated with glucocorticoids (GCs) and immunotherapy had a higher incidence of arrhythmias, in concert with the observations in myocardial injury, most likely through the same anti-inflammatory mechanism. **LIMITATIONS** One important limitation of our study is that it does not fully elaborate on whether patients were admitted to hospital with cardiac disease already, which could mean that we would be studying the consequences of cardiac disease rather than risk factors for cardiac disease. Although, we do attempt to elucidate this via each respective patient's medical history. In our study, timing is also crucial: our study is not strictly a cross-sectional study where variables present at the same time were observed - this study is about patients who all had COVID-19, and some also had heart disease around that time. It is important to know whether heart disease began before or after admission for COVID-19. CONCLUSION In conclusion, our study produced valuable clinical data related to the study of myocardial injury and arrhythmias in COVID-19 patients. We identified several risk factors associated with myocardial injury and arrhythmias in COVID-19 patients. Our findings provide potential markers for the further development of clinical guidance and treatment for COVID-19 patients with a considerable risk of developing severe cardiac manifestations. **Declaration of interests:** All authors declare no competing interests. **Acknowledgments:** We thank all the patients and their families, and the

clinical staff who treated the patients in Hannan, Enshi and Union medical

centres. We would also like to thank Troy Gharibani at University of Maryland,

USA for editing and providing feedback on this article.

281

282

283

see manuscript DOI for details

References

284

- 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
- Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H,
- Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features
- of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
- 289 2020;**395**(10223):497-506.
- 290 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W,
- Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel
- 292 Coronavirus Investigating and Research Team. A Novel Coronavirus from
- Patients with Pneumonia in China, 2019. The New England journal of medicine

ol for

- 294 2020;**382**(8):727-733.
- 295 3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,
- 296 Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138
- Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
- 298 Wuhan, China. JAMA 2020.
- 299 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X,
- Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical
- course and risk factors for mortality of adult inpatients with COVID-19 in
- Wuhan, China: a retrospective cohort study. Lancet
- 303 2020;**395**(10229):1054-1062.
- 5. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q,
- Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in
- Hospitalized Patients With COVID-19 in Wuhan, China. JAMA cardiology
- 307 2020.
- 6. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu
- 309 Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus
- Disease 2019 (COVID-19). JAMA cardiology 2020.

- 7. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ.
- Cardiac complications in patients with community-acquired pneumonia:
- incidence, timing, risk factors, and association with short-term mortality.
- 314 Circulation 2012;**125**(6):773-81.
- 8. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H,
- Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS.
- Pathological findings of COVID-19 associated with acute respiratory distress
- syndrome. The Lancet. Respiratory medicine 2020;8(4):420-422.
- 9. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk
- of myocardial infarction and stroke after acute infection or vaccination. The
- New England journal of medicine 2004;**351**(25):2611-8.
- 10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei
- Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of
- 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
- study. Lancet 2020;**395**(10223):507-513.
- 11. Guan WJ, Zhong NS. Clinical Characteristics of Covid-19 in China. Reply.
- The New England journal of medicine 2020;**382**.
- 12. Tokudome S, Sano M, Shinmura K, Matsuhashi T, Morizane S, Moriyama
- 329 H, Tamaki K, Hayashida K, Nakanishi H, Yoshikawa N, Shimizu N, Endo J,
- Katayama T, Murata M, Yuasa S, Kaneda R, Tomita K, Eguchi N, Urade Y,
- Asano K, Utsunomiya Y, Suzuki T, Taguchi R, Tanaka H, Fukuda K.
- 332 Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by
- activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis.
- The Journal of clinical investigation 2009;**119**(6):1477-88.
- 13. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ.
- 336 Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury
- in vivo. The Journal of clinical investigation 2001;**108**(4):585-90.

- 14. Takahashi T, Zhu SJ, Sumino H, Saegusa S, Nakahashi T, Iwai K,
- Morimoto S, Kanda T. Inhibition of cyclooxygenase-2 enhances myocardial
- damage in a mouse model of viral myocarditis. Life sciences
- 341 2005;**78**(2):195-204.
- 15. Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT,
- Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute
- myocardial infarction: Multiple players, dynamic roles, and novel therapeutic
- opportunities. Pharmacology & therapeutics 2018;186:73-87.
- 16. Karakas MS, Korucuk N, Tosun V, Altekin RE, Koç F, Ozbek SC, Ozel D,
- Ermis C. Red cell distribution width and neutrophil-to-lymphocyte ratio predict
- left ventricular dysfunction in acute anterior ST-segment elevation myocardial
- infarction. Journal of the Saudi Heart Association 2016;**28**(3):152-8.
- 17. Williams BA, Merhige ME. Association between neutrophil-lymphocyte
- ratio and impaired myocardial perfusion in patients with known or suspected
- coronary disease. Heart & lung: the journal of critical care 2013;**42**(6):436-41.
- 18. van Beek D, van der Horst I, de Geus AF, Mariani MA, Scheeren T.
- Albumin, a marker for post-operative myocardial damage in cardiac surgery.
- 355 Journal of critical care 2018;**47**:55-60.
- 19. Fagyas M, Úri K, Siket IM, Fülöp GÁ, Csató V, Daragó A, Boczán J, Bányai
- E, Szentkirályi IE, Maros TM, Szerafin T, Édes I, Papp Z, Tóth A. New
- perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin
- 359 suppresses angiotensin converting enzyme (ACE) activity in human. PloS one
- 360 2014;**9**(4):e87844.
- 20. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting
- enzyme inhibitors on mortality and morbidity in patients with heart failure.
- Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450-6.
- 21. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S.

365 Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of 366 367 three trials. Lancet 2006;368(9535):581-8. 368 22. Lazar HL, Volpe C, Bao Y, Rivers S, Vita JA, Keaney JF Jr. Beneficial 369 effects of angiotensin-converting enzyme inhibitors during acute 370 revascularization. The Annals of thoracic surgery 1998;66(2):487-92. 371 23. Lazar HL, Bao Y, Rivers S, Bernard SA. Pretreatment with 372 angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury. The Annals of thoracic surgery 2002;73(5):1522-7. 373 24. Furuhashi M, Ura N, Hasegawa K, Yoshida H, Tsuchihashi K, Nakata T, 374 Shimamoto K. Serum ratio of heart-type fatty acid-binding protein to myoglobin. 375 376 A novel marker of cardiac damage and volume overload in hemodialysis patients. Nephron. Clinical practice 2003;93(2):C69-74. 377

Table 1. Clinic Characteristics of Study Participants on Myocardial Injury and Arrhythmia

Characteristic	Myocardial	Injury	Arrhythmia	Arrhythmia		
	Yes	No	Yes	No		
Number (%)	80	401	71	410		
Age (years)			. 1	IDI		
≤40	3 (3.8)	110 (27.4)	2 (2.8)	111 (27.1)		
40-59	12 (15.0)	148 (36.9)	15 (21.1)	145 (35.4)		
60-79	52 (65.0)	128 (31.9)	44 (62.0)	136 (33.2)		
≥80	13 (16.2)	15 (3.7)	10 (14.1)	18 (4.4)		
Sex	71	15 (3.7) 196 (48.9)	0'O			
Female	24 (30.0)	196 (48.9)	24 (33.8)	196 (47.8)		
Male	56 (70.0)	205 (51.1)	47 (66.2)	214 (52.2)		
Male Smoking status Never	10					
Never	69 (86.2)	372 (92.8)	64 (90.1)	377 (92.0)		
Current	10 (12.5)	27 (6.7)	6 (8.5)	31 (7.6)		
Former	1 (1.2)	2 (0.5)	1 (1.4)	2 (0.5)		
The highest temperature (Mean, SD)	38.36	38.05	38.36	38.06		
The highest temperature (mean, e2)	(1.01)	(1.75)	(1.05)	(1.73)		
Signs and symptoms						
Fatigue	53 (66.2)	191 (47.6)	39 (54.9)	205 (50.0)		
Anorexia	51 (63.7)	264 (65.8)	40 (56.3)	275 (67.1)		
Dyspnea	51 (63.7)	60 (15.0)	51 (71.8)	60 (14.6)		
Disease severity						
Mild	2 (2.5)	270 (67.3)	3 (4.2)	269 (65.6)		
General	2 (2.5)	48 (12.0)	0 (0.0)	50 (12.2)		
Serious	76 (95.0)	83 (20.7)	68 (95.8)	91 (22.2)		
Outcomes		n				
Death	74 (92.5)	73 (18.2)	67 (94.4)	80 (19.5)		

Discharge	6 (7.5)	312 (77.8)	4 (5.6)	314 (76.6)
Still in hospital	0 (0.0)	16 (4.0)	0 (0.0)	16 (3.9)



Table 2 Multi-variable Analysis of putative risk factors for Myocardial Injury and Arrhythmia

Characteristic	Myocardial	Injury	OR	Adjusted. OR	Arrhythmia	OR		Adjusted. OR
	Yes	No	(95% CI)	(95% CI)	Yes	No	(95% CI)	(95% CI)
	n=80	n=401	15	71	n=71	n=410		
Age (years)					for de	, Since		
≤40	3 (3.8)	110 (27.4)		, 201	2 (2.8)	111 (27.1)		
40-59	12 (15.0)	148 (36.9)	2.97(0.82, 10.79)	2.07(0.55, 7.74)	15 (21.1)	145 (35.4)	5.74(1.29, 25.62)	5.07(1.12, 22.92)
60-79	52 (65.0)	128 (31.9)	14.9(4.53, 49.03)	9.78(2.85, 33.63)	44 (62.0)	136 (33.2)	17.96(4.26, 75.7)	14.59(3.35, 63.63)
≥80	13 (16.2)	15 (3.7)	31.78(8.1, 124.61)	18.85(4.37, 81.24)	10 (14.1)	18 (4.4)	30.83(6.24, 152.36)	17.51(3.23, 94.86)
Medical histories								
COPD	4 (5.0)	5 (1.2)	3.51(2, 6.16)	1.94(1.01, 3.71)	2 (2.8)	7 (1.7)	3.02(1.68, 5.45)	1.94(1, 3.75)
Heart disease	16 (20.0)	36 (9.0)	9.99(5.87, 17.02)	7.43(3.99, 13.83)	17 (23.9)	35 (8.5)	14.87(8.29, 26.7)	13.16(6.75, 25.68)
Diabetes	25 (31.2)	46 (11.5)	2.53(1.33, 4.84)	0.9(0.42, 1.9)	21 (29.6)	50 (12.2)	3.37(1.77, 6.43)	1.68(0.82, 3.43)
Hypertension	37 (46.2)	83 (20.7)	4.17(1.09, 15.88)	0.99(0.22, 4.54)	27 (38.0)	93 (22.7)	1.67(0.34, 8.2)	0.55(0.1, 3.11)
Cerebrovascular disease	9 (11.2)	7 (1.7)	3.3(2, 5.44)	1.26(0.69, 2.31)	8 (11.3)	8 (2.0)	2.09(1.23, 3.56)	0.72(0.38, 1.37)
Chronic kidney disease	7 (8.8)	10 (2.5)	7.13(2.57, 19.78)	2.06(0.65, 6.57)	5 (7.0)	12 (2.9)	6.38(2.31, 17.61)	2.78(0.87, 8.89)
Chronic liver disease	4 (5.0)	7 (1.7)	3.75(1.38, 10.17)	1.78(0.52, 6.06)	3 (4.2)	8 (2.0)	2.51(0.86, 7.36)	1.1(0.31, 3.88)
Others	15 (18.8)	48 (12.0)	2.96(0.85, 10.37)	4.73(1.07, 20.85)	6 (8.5)	57 (13.9)	2.22(0.57, 8.57)	2.54(0.6, 10.76)

Number of Comorbidities	2 (1.42)	0.75 (1.04)			1.85 (1.29)	0.80 (1.12)		
(mean, SD) Lab tests								
Aspartate aminotransferase (>40U/L)	42 (52.5)	121 (30.8)	1.7(0.9, 3.21)	1.33(0.61, 2.87)	37 (52.1)	126 (30.7)	0.57(0.24, 1.38)	0.3(0.11, 0.84)
Glutamyltranspeptidase (>50U/L)	21 (26.6)	96 (24.4)	2.13(1.74, 2.6)	2.14(1.37, 3.32)	17 (23.9)	100 (24.4)	1.82(1.5, 2.21)	1.85(1.19, 2.85)
Albumin (<40g/L)	66 (82.5)	103 (25.9)	2.48(1.52, 4.05)	1.5(0.85, 2.63)	50 (70.4)	119 (29.0)	2.45(1.47, 4.09)	1.48(0.84, 2.6)
Urea nitrogen (>8.1mmol/L)	41 (51.2)	43 (10.8)	1.12(0.65, 1.95)	0.97(0.52, 1.83)	27 (38.0)	57 (13.9)	0.98(0.54, 1.76)	0.84(0.44, 1.61)
Serum creatinine (>111µmol/L)	45 (56.2)	65 (16.3)	13.46(7.25, 24.98)	8.96(4.4, 18.23)	35 (49.3)	75 (18.3)	5.82(3.35, 10.12)	3.71(2.01, 6.85)
Serum sodium (<136mmol/L)	33 (41.2)	139 (35.1)	8.7(5.07, 14.95)	4.68(2.46, 8.91)	36 (50.7)	136 (33.2)	3.8(2.18, 6.62)	2.06(1.06, 4)
Treatments		see						
Oxygen therapy	51 (63.7)	254 (63.3)	6.61(3.95, 11.06)	4.55(2.44, 8.51)	43 (60.6)	262 (63.9)	4.34(2.56, 7.37)	3.11(1.65, 5.83)
Glucocorticoid therapy	61 (76.2)	165 (41.5)	1.3(0.79, 2.12)	0.83(0.47, 1.46)	50 (70.4)	176 (42.9)	2.07(1.25, 3.45)	1.43(0.82, 2.5)
Immunoglobulin therapy	39 (48.8)	109 (27.4)	1.02(0.62, 1.68)	0.75(0.42, 1.32)	26 (36.6)	122 (29.8)	0.87(0.52, 1.45)	0.63(0.36, 1.12)
Antibiotic therapy	70 (87.5)	350 (87.9)	4.53(2.61, 7.88)	3.07(1.58, 5.95)	63 (88.7)	357 (87.1)	3.17(1.83, 5.46)	2.03(1.1, 3.76)
Antiviral therapy	73 (91.2)	376 (94.5)	2.52(1.54, 4.12)	2.18(1.2, 3.93)	66 (93.0)	383 (93.4)	1.36(0.81, 2.31)	0.94(0.52, 1.72)
Outcomes								
Death	74 (92.5)	73 (18.2)			67 (94.4)	80 (19.5)		
Discharge	6 (7.5)	312 (77.8)	0.96(0.46, 1.99)	0.66(0.28, 1.57)	4 (5.6)	314 (76.6)	1.17(0.53, 2.58)	0.93(0.38, 2.28)

Still in hospital 0 (0.0) 16 (4.0) 0.61(0.25, 1.48) 0.73(0.24, 2.2) 0 (0.0) 16 (3.9) 0.93(0.35, 2.5) 1.19(0.38, 3.71)